Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Glycogen storage disease type Ia (GSD Ia, von Gierke disease): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Glycogen storage disease type Ia: the short answer

For glycogen storage disease type Ia, the US FDA has approved one medicine covered on this page, for a specific group of patients: Genglycos. Where a medicine is not registered in your country, the treating hospital can ask the national regulator for permission to import it for one named patient. Reserve Meds is a digital health company that helps families and hospitals with that process. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Genglycos.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Treatment at a qualified center, after a specialist referral.
Price: Quote on request.

What is glycogen storage disease type Ia?

Glycogen storage disease type I (von Gierke disease) is an inherited disorder in which a complex sugar called glycogen builds up in cells, especially in the liver, kidneys and small intestine. Signs usually appear at 3 to 4 months, when babies start to sleep longer between feeds. Babies can have low blood sugar, which can cause seizures, along with high lactic acid, uric acid and blood fats. Children may have an enlarged liver, short stature and thin arms and legs.^[1]

Type Ia is caused by variants in the G6PC1 gene and accounts for about 80 percent of type I cases. Overall incidence of type I is about 1 in 100,000. It is inherited in an autosomal recessive pattern.^[1]

Glycogen storage disease type Ia in the Gulf

A study from Tawam Hospital Metabolic Center in Abu Dhabi reviewed inborn errors of metabolism among Emiratis diagnosed from 1995 to 2013. Glycogen storage disease type Ia was among the most prevalent conditions, and among patients with these conditions who had mutation testing, 95 percent had homozygous mutations, which the authors said justifies genetic counseling and screening programs.^[2]

Genglycos is a gene therapy approved by the FDA on 19 August 2026. On 17 October 2026 it was not found in the SFDA drugs list or the Abu Dhabi Department of Health drug code list.^{[3, 4, 5]}

US FDA-approved medicines for glycogen storage disease type Ia

Each medicine below is approved in the US for a specific group of patients. The wording follows the current US label. Your specialist decides whether any of them is right for the patient.

Genglycos (pariglasgene brecaparvovec-opnr)
FDA-approved for reducing daily cornstarch intake, as an add-on to nutritional management, in adults and children aged 8 and older with glycogen storage disease type Ia. It is a gene therapy.^[3]
US FDA approval: 19 August 2026. Gulf registers: Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked.^{[4, 5]}

How families in the Gulf can access these medicines

For Genglycos. These are made for one patient or given through a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center abroad that can give the treatment. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves the import. We cannot promise that a manufacturer will agree.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why this medicine is being considered
Reports that confirm the diagnosis, such as genetic, pathology or laboratory results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for glycogen storage disease type Ia

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is there an FDA-approved treatment for glycogen storage disease type Ia?

Yes. The medicine on this page has US FDA approval for a specific group of patients: Genglycos. The exact conditions are in the US label and are summarized above. Your specialist decides whether it fits.

Is Genglycos available in Saudi Arabia or the UAE?

Saudi Arabia: not found in the SFDA drugs list. Abu Dhabi: not found in the Abu Dhabi DoH drug code list. Checked 17 October 2026. Kuwait, Qatar and Oman: no public register checked. A listing in Abu Dhabi does not show federal UAE status, which we could not verify.

How can a family in the Gulf get Genglycos?

It is given at a qualified center. Your specialist refers the patient, the center checks eligibility, and the family plans funding and travel. A local hospital can only give it if the manufacturer agrees to supply it and the regulator approves the import.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Does Reserve Meds diagnose or prescribe?

No. Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We do not diagnose, prescribe or decide what a regulator approves. Your specialist and hospital make the medical decisions.

Does Genglycos replace cornstarch and diet?

Not completely. The FDA approval is to reduce daily cornstarch intake as an add-on to nutritional management, in patients aged 8 and older. Your metabolic team will guide any change in diet.

Sources for the last answer: ^[3]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.